Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eurobio Scientific
Finance Watch: New Funds Keep Venture Capital Flowing Into Biopharma
Private Company Edition: In the first week of April, Cure Ventures launched with a $350m fund, the Alzheimer’s Drug Discovery Fund received $200m for its venture philanthropy strategy and Canaan revealed $850m in new funds. Also, OnKure raised $53.7m and Phlow closed a $36m series B round.
Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Dealmaking Quarterly Statistics, Q3 2022
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Doctors Frustrated By Lack Of Guidance On Who Should Get Aduhelm
Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.
- In Vitro Diagnostics
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- ExonHit Therapeutics Inc.
- Ingen BioSciences, Diaxonhit Group
- TECOmedical AG
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.